EUCTR2021-000603-21-PL
Active, not recruiting
Phase 1
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) - DESTINY-Breast11
ConditionsEarly stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)MedDRA version: 21.0Level: LLTClassification code 10025541Term: Malignant breast neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)
- Sponsor
- AstraZeneca AB
- Enrollment
- 900
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Key Inclusion Criteria:
- •\- Patients must be at least 18 years of age.
- •\- Histologically documented HER2\-positive EBC participants with:
- •(a) Locally assessed HER2\-positive (IHC 3\+ or ISH\+) according to ASCO\-CAP guidelines and prospectively centrally confirmed as HER2 positive based on a tumour sample
- •(b) Unifocal and multifocal tumours (\> 1 tumour confined to the same quadrant as the primary tumour) must have 1 focus sampled and centrally confirmed as HER2 positive
- •(c) Multi\-centric tumours (multiple tumours involving \> 1 quadrant of the breast) must have 1 lesion from each involved quadrant sampled and centrally confirmed as HER2 positive. All quadrants tested must be centrally confirmed as HER2 positive
- •(d) Tumours documented as HR\-positive (either ER and/or PgR positive \[ER or PgR \= 1%]) or HR\-negative (ER and PgR negative) by local assessment per ASCO\-CAP guidelines (Allison et al 2020\)
- •(e) Clinical stage at presentation (based on mammogram or breast MRI assessment): T0\-4 (inclusive of inflammatory breast cancer), N1\-3, M0 or \= T3, N0, M0 as determined by the AJCC staging system, 8th edition (Hortobagyi et al 2017\)
- •(f) Pathologic confirmation of nodal involvement with malignancy as determined by fine\-needle aspiration or core\-needle biopsy, when applicable.
- •\- FFPE tissue block (2 cores) or 20 freshly\-cut, serial tumor slides for HER2 assessment by central lab. If blocks are incomplete or fewer than 20 slides are available, participants may be eligible following discussion with the AstraZeneca Study Physician?
Exclusion Criteria
- •Key Exclusion Criteria:
- •\- Prior history of invasive breast cancer
- •\- Any primary malignancy within 3 years, except adequately resected non\-melanoma skin cancer, or curatively treated in situ disease
- •Note: This includes a second current breast primary malignancy (ie, bilateral breast cancer)
- •\- History of DCIS, except for participants treated with mastectomy only \> 5 years prior to current diagnosis
- •\- Prior sentinel lymph node biopsy or axillary lymph node dissection before initiation of neoadjuvant treatment
- •\- Prior systemic therapy for the treatment of breast cancer
- •\- Previous treatment with anthracyclines, cyclophosphamide or taxanes for any malignancy; cyclophosphamide allowed for non\-cancer treatment if last dose \> 6 months
- •\- Ineligible for any medication in the control Arm C
- •\- Any concurrent anticancer treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
A Phase 3 Trial of Neoadjuvant T-DXd Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)HER2-positive early breast cancerJPRN-jRCT2041210097Inoguchi Akihiro900
Active, not recruiting
Phase 3
Global open label phase-III study having 3 treatment arm in neoadjuvant setting in Patients with High-risk HER 2-positive Early-stage Breast CancerHealth Condition 1: C509- Malignant neoplasm of breast of unspecified siteCTRI/2022/01/039210ASTRAZENECA AB
Recruiting
Phase 3
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)C50 Cancer de mamaPER-067-21AstraZeneca AB22
Active, not recruiting
Phase 1
DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of care treatment (ddAC-THP) and determine its safety and efficacy in patients with HER2-positive early breast cancer.Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)MedDRA version: 21.0Level: LLTClassification code 10025541Term: Malignant breast neoplasmSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-000603-21-ITASTRAZENECA AB624
Active, not recruiting
Phase 1
DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of care treatment (ddAC-THP) and determine its safety and efficacy in patients with HER2-positive early breast cancer.Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)MedDRA version: 21.0Level: LLTClassification code 10025541Term: Malignant breast neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-000603-21-DEAstraZeneca AB900